期刊
CLINICAL SCIENCE
卷 124, 期 5-6, 页码 343-349出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20120304
关键词
glycated low-density lipoprotein; small dense low-density lipoprotein; statin; Type 2 diabetes mellitus
资金
- British Heart Foundation [PG/04/088/17423]
- Manchester Academic Health Sciences Centre (MAHSC)
Glycation of apoB (apolipoprotein B) of LDL (low-density lipoprotein) increases its atherogenicity. Concentrations of both serum glyc-apoB (glycated apoB) and SD-LDL (small dense LDL) (syn LDL3; D=1.044-1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin- and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20 +/- 2 (means +/- S.D.) and 3.6 +/- 0.41 compared with 47 +/- 3 and 5.89 +/- 0.68 mg/dl in those not receiving statins (P < 0.001 and <0.01, respectively). There was a dose-dependent increase in glycation on incubation of LDL subfractions with glucose, which was accompanied by an increase in LPO (lipid peroxide) and electrophoretic mobility and a decrease in free amino groups. SD-LDL was more susceptible to these changes than more buoyant LDL. Both SD-LDL and more buoyant LDL from statin-treated patients were less susceptible to glycation. There were fewer free amino groups on LDL subfractions from statin-treated patients, which may contribute to this resistance. In conclusion, greater susceptibility of SD-LDL to glycation is likely to contribute to the raised levels of circulating glyc-apoB in diabetes. Statins are associated with lower levels of both SD-LDL and glyc-apoB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据